Health Insurance Innovations remains a top pick, says Canaccord. Canaccord analyst Richard Close said the magnitude of the pullback in Health Insurance Innovations following its beat and raise Q1 report was surprising. He said it the company remains a top pick as the outlook is improving with a likely near-term resolution to the multi-state investigation, probable reversal of the 3-month duration limit on short term medical, and the individual mandate penalty going away in 2019. Close reiterated his Buy rating and $55 price target on Health Insurance Innovations shares
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.